UBS Group
EXOZ

UBS Group’s eXoZymes Inc EXOZ Stock Holding History

UBS Group’s Portfolio EXOZ Stock Details EXOZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71K Buy
203
+179
+746% +$1.69K ﹤0.01% 9489
2026
Q1 		$180 Buy
24
+21
+700% +$192 ﹤0.01% 10047
2025
Q4 		$33 Sell
3
-4,618
-100% -$63.7K ﹤0.01% 10309
2025
Q3 		$66.7K Sell
4,621
-393
-8% -$4.28K ﹤0.01% 7372
2025
Q2 		$49.5K Buy
5,014
+4,851
+2,976% +$59.2K ﹤0.01% 7781
2025
Q1 		$1.7K Sell
163
-544
-77% -$8.08K ﹤0.01% 9461
2024
Q4 		$11.7K Buy
+707
New +$10.4K ﹤0.01% 8233

Other funds holding EXOZ

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DKCM
Davidson Kahn Capital Management Sherman Oaks, California $233M AUM 19.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Group's EXOZ Position: Q2 2026 in Review

UBS Group increased its eXoZymes Inc (EXOZ) stake by 746% in Q2 2026, buying an estimated $1.69K and bringing the position to 203 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #9489.

UBS Group first reported a position in EXOZ in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.7K in Q3 2025. 9 funds tracked by Wall St. Rank hold EXOZ as of Q2 2026.

  • UBS Group held 203 shares of eXoZymes Inc worth $1.71K as of Q2 2026.
  • UBS Group bought 179 eXoZymes Inc shares in Q2 2026, an estimated $1.69K.
  • eXoZymes Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9489 holding.
  • UBS Group first reported a position in eXoZymes Inc in Q4 2024 and has held it in 7 quarters since.
  • UBS Group's eXoZymes Inc position peaked at $66.7K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held eXoZymes Inc as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.